Key facts
- This page summarizes Chase LoPriore's Form 3 filing for Hepion Pharmaceuticals, Inc. (HEPA).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 26 May 2026, 17:00.
Chase LoPriore - 16 Mar 2026 Form 3 Insider Report for Hepion Pharmaceuticals, Inc. (HEPA)
- Reporting relationship
- Director
- Issuer ticker
- HEPA
- Reported as of
- 16 Mar 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 26 May 2026, 17:00:17 UTC
- Next SEC filing
- 21 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Chase LoPriore
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Chase LoPriore filed Form 3 for Hepion Pharmaceuticals, Inc. (HEPA) on 26 May 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002136903
Primary reporting owner
LoPriore Chase
- Relationship
- Director
- Address
- C/O HEPION PHARMACEUTICALS, INC., 34 SHREWSBURY AVE., SUITE 1D, RED BANK
- Signature
- /s/ Chase LoPriore
- Signature date
- 26 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HEPA
holding
Common Stock, par value $0.0001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,250,000
- Date
- 16 Mar 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.